IMMUNIC, INC. Logo

IMMUNIC, INC.

Developing oral small molecule therapies for chronic inflammatory and autoimmune diseases.

IMUX | US

Overview

Corporate Details

ISIN(s):
US4525EP1011 (+1 more)
LEI:
549300R5T12FW5MEQB20
Country:
United States of America
Address:
1200 AVENUE OF THE AMERICAS, 10036 NEW YORK
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Immunic, Inc. is a clinical-stage biotechnology company developing a pipeline of selective, orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company focuses on creating differentiated programs to address unmet patient needs in conditions such as multiple sclerosis and celiac disease. Its mission is to develop high-quality, oral treatment options with comprehensive therapeutic efficacy and favorable safety and tolerability profiles, aiming to elevate the standard of care for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 12:30
Earnings Release
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corpora…
English 22.9 KB
2025-10-29 11:30
Regulatory News Service
Immunic to Participate in Industry and Investor Conferences in November
English 9.7 KB
2025-10-01 12:30
Regulatory News Service
Immunic to Participate in Scientific and Investor Conferences in October
English 14.9 KB
2025-09-25 12:30
Regulatory News Service
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS…
English 23.6 KB
2025-09-09 12:30
Regulatory News Service
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofl…
English 13.9 KB
2025-09-04 12:30
Regulatory News Service
Immunic to Participate in Investor and Scientific Conferences in September
English 15.6 KB
2025-08-07 12:30
Earnings Release
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corpor…
English 23.5 KB
2025-06-24 12:30
Regulatory News Service
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 …
English 15.2 KB
2025-06-05 12:30
Legal Proceedings Report
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Re…
English 18.3 KB
2025-06-02 12:30
Regulatory News Service
Immunic to Participate in Investor, Scientific and Industry Conferences in June
English 13.9 KB

Automate Your Workflow. Get a real-time feed of all IMMUNIC, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IMMUNIC, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IMMUNIC, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.